Biocracked
Approach: Lab in action. Palette: B, warm.

Close, slightly high three-quarter angle on an isolated rat heart suspended in a Langendorff perfusion rig, the small dark-red heart held by its aorta on a glass cannula inside a warm-jacketed glass chamber. Clear perfusion fluid drips from the heart and beads on the glass. A gloved hand in the soft-focus foreground adjusts a stopcock. Amber, honey-colored light from a low side lamp rakes across the curved glass, producing copper highlights and warm brown shadows. Behind it, a blurred bench holds tubing and a small pressure transducer. A thin electric green (#00e676) indicator light glows on the instrument at the edge of the frame. Mood: quiet, focused, cautiously hopeful, with real laboratory texture and shallow depth of field. No text or labels.
Longevity

Two Popular Supplements Shielded Old Rat Hearts. Here's the Catch

Dr. Synapse · · 4 min read

A pair of supplements you can buy online helped isolated hearts from aged rats recover from a heart-attack-style injury. Together they worked better than either one alone. That is the headline result of a new paper in Veterinary Research Forum. It comes with a large caveat: the work was done in rats, on hearts studied outside the body, so it says nothing yet about people.

What the researchers tested

The study, led by Amanzadeh and colleagues at Urmia and Tabriz Universities of Medical Sciences in Iran, looked at melatonin and nicotinamide mononucleotide (NMN). Each has shown heart-protective properties in earlier research, but the authors note that their combined effect on ischemia-reperfusion (IR) injury in the aged heart was unclear.

IR injury is the damage that occurs when blood supply to heart tissue is cut off (ischemia) and then restored (reperfusion). Restoring flow is essential, yet the sudden return can trigger inflammation and further injury. It is a central problem in heart attacks and in cardiac procedures. Age makes things worse, since the paper opens by noting that aging markedly raises vulnerability to cardiovascular disorders such as acute coronary syndrome and coronary artery disease.

How the experiment worked

  • Animals: 40 male Wistar rats, split into five groups of eight: Sham (no injury), IR (injury only), melatonin plus IR, NMN plus IR, and NMN plus melatonin plus IR.
  • Injury: hearts underwent 30 minutes of ischemia, then reperfusion.
  • Melatonin: given at 50 µM in the reperfusion solution for 15 minutes after the ischemic period. It was delivered straight into the heart's perfusion fluid, not taken as a pill.
  • NMN: given by intraperitoneal injection (into the abdominal cavity) at 100 mg/kg every other day for 28 days.
  • Measurements: coronary flow, heart rate, left ventricular end-diastolic pressure, and left ventricular developed pressure. The team also measured creatine kinase, a marker of muscle injury, and the inflammatory markers IL-1β, IL-6, tumor necrosis factor-alpha, and NF-κB.

What they found

Injury alone significantly impaired coronary flow and heart rate. Both melatonin and NMN improved these measures.

Both agents also lowered left ventricular end-diastolic pressure and improved recovery of left ventricular developed pressure. The combination produced the greatest effect on these measures.

The biochemical results followed the same pattern. Creatine kinase and the inflammatory markers rose significantly in the untreated IR group. Treatment markedly reduced them, and combined treatment did so most. The authors conclude that melatonin and NMN have additive cardioprotective effects against IR injury in aged rats.

Why the combination is interesting

NMN is a precursor to NAD+, a molecule involved in cellular energy metabolism that has become a staple of longevity discussions. Melatonin is best known as a sleep-related hormone and is one of the most widely used over-the-counter supplements. Both are popular in the healthy-aging space, which makes any study pairing them attractive.

The paper's finding is more modest than the hype around either compound. It shows that in this rat model the two treatments, given together, outperformed each given alone on several measures of function and inflammation. It does not show that this is how they would act in a human heart, and the abstract does not claim so.

Limits you should not skip

This is animal, ex vivo research. The hearts were assessed as isolated organs, so there was no circulating blood, no full immune response, and none of the complexity of a living patient with other conditions and medications.

The delivery routes are not supplement-like. Melatonin went into the perfusion fluid at a fixed concentration for a short window. NMN was injected into the abdomen. Neither mirrors swallowing a capsule, and the study cannot be translated into an oral human dose.

Small, single-sex samples. Eight rats per group, all male, is a standard design for early work but limits how far the findings generalize. The abstract also describes the animals as "adult male Wistar rats" while the title and aims refer to aged rats, so the exact age of the animals is worth checking in the full text.

The abstract is limited on mechanism. It reports reduced inflammatory markers and better function, but it does not establish exactly how the two compounds interact. It also does not mention other outcomes, such as infarct size, in the summary.

The timing differs between the two agents. NMN was a four-week pretreatment, while melatonin was given only at reperfusion. This makes it hard to say what the benefit would look like in a real emergency, which usually cannot be planned for.

The authors report no competing financial interests.

Practical takeaways

  • Dose: there is no human dose to take from this paper. The rat doses (100 mg/kg NMN by injection, 50 µM melatonin in perfusate) are not human supplement doses and should not be converted into one.
  • Timing: in the study, NMN was given every other day for 28 days beforehand and melatonin during reperfusion. That protocol is a laboratory design, not guidance.
  • Who it's for: at this stage, researchers, not consumers. People with heart disease, or anyone taking cardiac medications or blood thinners, should talk to a clinician before adding supplements. Neither compound is a substitute for emergency care or established treatment.
  • What to watch for: studies in living animals, then human trials with clinical outcomes. Those will show whether this additive effect survives outside an isolated heart.

Bottom line

The study adds to the case that NAD+ support and melatonin deserve further investigation as heart-protective strategies in aging. It is an encouraging preclinical signal and nothing more. Until the work is repeated in living animals and tested in people, treat it as an interesting lead rather than a reason to change your supplement routine.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Conceptual metaphor in a bold color field palette: a single vintage analog wall clock with a plain, unmarked white face, photographed straight on against a saturated mustard-yellow backdrop. The hands are visibly bent and slightly loose, and a thin strip of translucent tape holds the hands at a different position. A small pile of eight tiny brass gears sits at the base, with one gear glowing electric green (#00e676) as the lone accent. Lighting is hard, direct studio flash from the upper left, casting a crisp, graphic shadow of the clock onto the yellow wall. Slight macro depth of field blurs the gears in front. Mood is skeptical, curious and playful, suggesting a claim that deserves scrutiny. Photorealistic, with real metal and glass reflections and no text or numerals.
supplements

NMN + BHB + Ginsenosides: The '4-Year Younger' Clock Claim, Decoded

BY NOVA CHEN ·

A multi-ingredient NMN stack with BHB and ginsenosides was tied to a roughly 4-year drop in the DNAm PhenoAge epigenetic clock. The catch is that the figure came from an uncontrolled pilot of just eight people, and the authors say it does not establish age reversal. The main 42-day trial had about 10 people per arm, was open-label, and found no significant between-group improvements in cardiopulmonary or cognitive outcomes. This article breaks down what the study did show, the conflict-of-interest details, and how to read clock claims on supplement labels.

**Approach:** Conceptual metaphor. **Palette:** D, bold color field.

A single AA-style battery stands upright on a saturated tomato-red matte backdrop. Its casing is cleanly cut away so the cells inside show as a real cross-section. A thin, steady bead of electric green gel or liquid sits at a constant level inside the cell. Beside it, a worn analog pressure gauge on a rubber tube, its needle pushed into the upper range, stands for hypertension. A white coiled stethoscope tubing curls loosely across the foreground.

Shot at a slightly low, eye-level three-quarter angle with a 50mm lens and shallow depth of field. Lighting is hard, crisp studio key light from the upper left. It casts sharp, warm-neutral shadows on the red surface and bright specular highlights on the metal.

The mood is skeptical and analytical: stable, not draining, with the real warning sign sitting next to it.
longevity

Blood NAD Doesn't Fall With Age. It Tracks Heart Disease Instead

BY DR. SYNAPSE ·

The standard pitch for NAD supplements is that your levels fall as you age, so you need to top them up. A large new Nature Metabolism study of 1,068 adults found that whole-blood NAD does not decline with age in healthy people. It stays stable in men and actually rises in women. What does track with lower NAD is cardiovascular disease and hypertension. The authors stress that this does not prove NAD supplementation treats either condition.

Approach: the human outcome. Palette: natural.

A tight, low-angle shot of an elderly person's hands gripping a smooth wooden cane at the top of a sunlit garden path. The hands are weathered and slightly tremulous, with visible veins and thin, spotted skin. Behind them, the blurred figure of a seated older man in a cardigan is just recognizable, with his face out of frame. Warm late-morning daylight comes from the side and picks out the grain of the wood and the texture of the skin. The background is soft green foliage and a gravel path in shallow depth of field. The tones are plant greens, honeyed wood and natural skin. A single fresh leaf in vivid electric green sits in the lower foreground. The mood is quiet, honest and reflective, and it suggests fragility without drama.
longevity

Frail Seniors Had Lower Blood NAD+. What That Means for NMN/NR

BY HELIX WARD ·

A new GeroScience study of 529 older Japanese adults found that those with frailty had slightly lower NAD+ in their blood, with about 13% lower odds of frailty per 1 µmol/L increase. But the study was cross-sectional, included only 32 frail participants, and the difference in medians was just 24 versus 25 µmol/L. The link also weakened after adjusting for hematocrit, suggesting blood cell composition may explain part of it. Here is what the findings really say, why they don't show that NMN or NR prevent frailty, and what to consider if you're thinking about NAD precursors.

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Calmed 'Old' Platelets in Aged Mice—Here's the Catch

BY NOVA CHEN ·

A new Aging Cell study reports that CoQ10 improved the function of aged megakaryocytes, the bone marrow cells that make platelets, in mice. Treated animals showed reduced platelet aggregation and activation, though platelet counts didn't change. The effect appeared to run partly through COPS3 and autophagy, the cell's recycling system. But this was mouse and cell-line research with no human data and no proof of clot prevention. Here is what it means, what it doesn't, and why people on blood thinners should talk to a doctor first.

This page is available in